Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination. The terms of the EUA allow use of the vaccine while more data are gathered. The Company plans to file for a Biologics License Application (BLA) with the FDA later in 2021. “This milestone follows a year of incredible work by our dedicated teams and unprecedented collaboration with health leaders around the world – all of whom shared a goal of bringing a single-shot vaccine to the public,” said Alex Gorsky, Chairman and Chief Executive Officer at Johnson & Johnson. “We will do everything we can to help bring this pandemic to an end, in the United States and throughout the world.”“We believe the Johnson & Johnson single-shot COVID-19 vaccine is a critical tool for fighting this global pandemic, particularly as it shows protection across countries with different...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
More News: Allergy | Allergy & Immunology | Biotechnology | Bleeding | Brain | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Chemistry | Clinical Trials | Contracts | Coronavirus | COVID-19 | Department of Health | Ebola | Ebola Vaccine | Emergency Medicine | Environmental Health | European Medicines Agency (EMA) | Flu Pandemic | Food and Drug Administration (FDA) | Government | Headache | Health Management | Heart | Hospitals | Hypertension | Infectious Diseases | Influenza | Influenza Vaccine | International Medicine & Public Health | Learning | Legislation | Marketing | Men | Migraine | National Institutes of Health (NIH) | Neurology | Neuroscience | Pain | Pandemics | Pharmaceuticals | Pregnancy | Profits and Losses | Pulmonary Hypertension | Respiratory Medicine | SARS | Science | Skin | Study | Universities & Medical Training | USA Health | Vaccines | WHO | Zika Virus